

Prevalence of *Salmonella enterica* in Poultry and Eggs in Uruguay during an Epidemic Due to *Salmonella enterica* Serovar Enteritidis[▽]

L. Betancor,^{1,2†} M. Pereira,^{1,2†} A. Martinez,^{1,2} G. Giossa,³ M. Fookes,⁴ K. Flores,¹ P. Barrios,¹ V. Repiso,⁵ R. Vignoli,¹ N. Cordeiro,¹ G. Algorta,¹ N. Thomson,⁴ D. Maskell,⁶ F. Schelotto,^{1‡} and J. A. Chabalgoity^{2‡*}

Bacteriology and Virology Department¹ and Biotechnology Department,² Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay; Department of Avian Pathology, Veterinary Faculty, Universidad de la República, Montevideo, Uruguay³; DILAVE, Central Veterinary Laboratories, Ministry of Agriculture, Montevideo, Uruguay⁴; The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom⁵; and Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, United Kingdom⁶

Received 2 November 2009/Returned for modification 2 January 2010/Accepted 10 May 2010

Salmonella enterica serovar Enteritidis (*S. Enteritidis*) is frequently associated with food-borne disease worldwide. Poultry-derived products are a major source. An epidemic of human infection with *S. Enteritidis* occurred in Uruguay, and to evaluate the extent of poultry contamination, we conducted a nationwide survey over 2 years that included the analysis of sera from 5,751 birds and 12,400 eggs. Serological evidence of infection with *Salmonella* group O:9 was found in 24.4% of the birds. All positive sera were retested with a gm flagellum-based enzyme-linked immunosorbent assay, and based on these results, the national prevalence of *S. Enteritidis* infection was estimated to be 6.3%. *Salmonellae* were recovered from 58 of 620 pools made up of 20 eggs each, demonstrating a prevalence of at least 1 in every 214 eggs. Surprisingly, the majority of the isolates were not *S. Enteritidis*. Thirty-nine isolates were typed as *S. Derby*, 9 as *S. Gallinarum*, 8 as *S. Enteritidis*, and 2 as *S. Panama*. Despite the highest prevalence in eggs, *S. Derby* was not isolated from humans in the period of analysis, suggesting a low capacity to infect humans. Microarray-based comparative genomic hybridization analysis of *S. Derby* and *S. Enteritidis* revealed more than 350 genetic differences. *S. Derby* lacked pathogenicity islands 13 and 14, the fimbrial *lpf* operon, and other regions encoding metabolic functions. Several of these regions are present not only in serovar Enteritidis but also in all sequenced strains of *S. Typhimurium*, suggesting that these regions might be related to the capacity of *Salmonella* to cause food-borne disease.

Salmonella enterica is a major cause of food-borne disease worldwide (14, 18, 46). Poultry-derived products, particularly chicken eggs, are considered a major source of human infection with *Salmonella* (2, 20, 38). Chickens can be infected with many different serovars of *Salmonella*. Of these, *S. enterica* serovars Pullorum and Gallinarum (*S. Pullorum* and *S. Gallinarum*, respectively) are host specific and represent a major concern for the poultry industry but have no impact on public health. Other *S. enterica* serovars frequently isolated from chickens, such as Typhimurium, Enteritidis, and Heidelberg, can infect a wider range of hosts and frequently reach the human food chain, causing food-borne disease.

A peculiar epidemiological feature of human salmonellosis is that epidemics are commonly associated with a particular prevalent serovar of *S. enterica* that shows temporal and geographical variation. Until the 1980s, *S. enterica* serovar Typhimurium (*S. Typhimurium*) was the serovar most commonly isolated from humans worldwide, but by the late 1980s, *S.*

enterica serovar Enteritidis (*S. Enteritidis*) emerged as the most common cause of salmonellosis in Europe, and during the 1990s, it became the most prevalent serovar in many countries worldwide (9, 22, 33, 40, 43). The reasons for this worldwide serovar shift are still not understood, and several hypotheses have been proposed, including the existence of a rodent reservoir for *S. Enteritidis* or the epidemiological change induced by vaccination of poultry against the closely related bacterium *S. Gallinarum* (47).

In Uruguay, *S. Typhimurium* was the most frequently isolated serovar until 1994, and *S. Enteritidis* was only sporadically isolated (3, 24, 37). In 1995, a first outbreak of *S. Enteritidis* occurred, starting an epidemic that lasted almost 10 years. This outbreak was traced back to sandwiches prepared with contaminated mayonnaise that were distributed nationwide by a local catering service. According to data provided by the national public health authorities, the outbreak affected an estimated 600 individuals countrywide. From then on, several other outbreaks of various sizes occurred and *S. Enteritidis* was identified as the cause in 89% of *Salmonella* food poisoning episodes. In most of these cases (80%, according to official records), eggs or chicken meat was identified as the source of infection. From 1997 to 2004, *S. Enteritidis* was the most frequently identified serovar in Uruguay, accounting for more than 50% of the strains received each year at the National *Salmonella* Center and for more than 85% of the strains isolated from humans (3). After 2005, there was a dramatic re-

* Corresponding author. Mailing address: Biotechnology Department, Instituto de Higiene, Facultad de Medicina, Universidad de la República Uruguay, Av. Alfredo Navarro 3051, CP 11600, Montevideo, Uruguay. Phone: 598-2 4871288, ext. 1120. Fax: 598-2 4873073. E-mail: jachabal@higiene.edu.uy.

† L.B. and M.P. contributed equally to this work.

‡ F.S. and J.A.C. share the senior authorship of this work.

[▽] Published ahead of print on 19 May 2010.

duction in the number of *S. Enteritidis* outbreaks, and this year was considered the end of the epidemic. Over the last 3 years, *S. Typhimurium* has become the serovar most frequently associated with isolated cases of food poisoning, and *S. Derby* and *S. Panama* have been sporadically isolated. Nevertheless, *S. Enteritidis* is still the serovar most frequently associated with outbreaks in the country.

S. Enteritidis frequently colonizes the alimentary tracts of chickens without causing disease. However, it can produce a systemic infection in young chicks that may further lead to the infection of egg contents (13, 51). With the aim of knowing the prevalence of *S. Enteritidis* infection in poultry, we designed and conducted a countrywide serological and microbiological survey of chicken flocks and commercially available eggs from 2000 to 2002, and the results are presented here. An unexpected result of the survey was a higher prevalence of *S. Derby* than *S. Enteritidis* in eggs, particularly because while the latter was identified as the etiological agent of the epidemic there were no reports of human infections with *S. Derby* in the same period of time. This suggested a low capacity of *S. Derby* isolates to infect humans; thus, we performed a genomic comparison of the two serovars to search for genetic differences that could be the basis of such marked differences in epidemiological behavior. We found that *S. Derby* lacks several genomic regions related to virulence, suggesting that these regions could be involved in the capacity of *Salmonella* to cause food-borne disease.

MATERIALS AND METHODS

Serological survey. A serological survey for the detection of antibodies against *Salmonella* O:9 lipopolysaccharide (LPS) was conducted on a representative sample of Uruguayan breeding and commercial egg-laying flocks. The size of the sample was defined with statistical criteria, considering a whole population of approximately 2,500,000 laying hens and 250,000 breeders. Based on preliminary estimations, we assumed an expected prevalence of infection of 5% among laying birds and 2% among breeders. A sampling error of 0.2% and a confidence interval of 95% were taken into account in defining the extent of the sampling regimen. Based on these assumptions, a total of 34 flocks (20 layer and 14 breeder flocks) from the 664 flocks in the country were selected for sampling, and from these, 5,751 hens were randomly selected using a stratified random sampling methodology. The selected farms were located in 7 of the 19 Departments into which Uruguay is divided and were geographically representative of all of the major poultry production areas.

A questionnaire was administered along with the survey to build a database containing information from each farm surveyed, including the history of previous vaccination with a locally available product, i.e., 9R (Nobilis SG 9R; Hoechst Roussel-Intervet) or inactivated *S. Enteritidis* (SEI; Ciencia Lab, Meril) vaccine. Table 1 shows data from all of the sampled flocks and farms.

Blood was obtained from the wing vein, and serum was separated. Labeled coded samples were stored in freezer boxes at -20°C until assessed. Sera were evaluated double blind for serological evidence of infection using two different screening methods, an *S. Enteritidis* LPS enzyme-linked immunosorbent assay (ELISA) (a modification of the method described by Nicholas and Cullen in 1991 [35]) and agglutination by Rapid Slide Test (RST) using locally produced *S. Pullorum-S. Gallinarum* polyvalent somatic antigens as described by the Office International des Epizooties (48).

All sera yielding a positive result by any of the screening methods were also evaluated by a commercial ELISA kit that assesses antibodies against gm flagellin antigens (gm ELISA, *Salmonella* Enteritidis antibody test kit, FlockChek Se assay; IDEXX Laboratories, Inc., Westbrook, ME).

LPS ELISA. Sera were analyzed using a modification of a previously described method (35). Briefly, microtiter plates were coated with 50 μl of LPS solution at 5 $\mu\text{g}/\text{ml}$ (LPS from *Salmonella* Enteritidis; Sigma Chemical Co., St. Louis, MO) in coating buffer (0.05 M carbonate-bicarbonate buffer, pH 9.6) and incubated for 1 h at 37°C . The plates were washed five times in phosphate-buffered saline (PBS) containing 0.05% Tween 20. Test and control sera were diluted 1/1,000 in PBS-Tween buffer with 1% bovine serum albumin and assayed in duplicate using

TABLE 1. Description of serological and microbiological sampling^a

Type of hen and farm sampled ^b	No. of sera tested ^c	No. of eggs sampled ^d	Vaccination ^e
Layers			
A	189	1,200	No
B	183	600	9R
C (5 flocks)	949	800	9R
D	189	600	No
E	186	700	No
F	0	600	NA
G (2 flocks)	339	600	No
H	181	700	No
I	0	500	NA
J	0	500	NA
K	183	500	No
L	189	700	No
M	0	400	NA
N	191	600	SEI
\bar{N}	198	400	No
O	0	400	NA
P	0	500	NA
Q	181	400	No
R	0	700	NA
S	182	600	No
T	189	400	No
7	185	0	No
Layer-breeders			
14	153		No
19	139		No
20	151		No
26	99		9R
27	99		9R
30	149		No
31	151		No
33	168		No
34	157		No
Broiler-breeders			
2	150		9R
3	153		No
4	158		SEI
25	160		9R + SEI
32	150		SEI

^a Data from environmental and cloacal swabs are not included. Each flock was sampled for 60 cloacal swabs and 1 environmental swab.

^b A total of 41 flocks were tested.

^c A total of 5,751 sera from 34 flocks were tested.

^d A total of 12,400 eggs from 21 layer farms were tested.

^e NA, no available data. 9R, *S. Gallinarum* rough strain 9R vaccine. SEI, *S. Enteritidis* inactivated vaccine.

50 μl per well. Plates were incubated for 1 h at 37°C and then washed as before. A solution of goat anti-chicken IgG conjugated to peroxidase (Bethyl Laboratories, Inc., Montgomery, TX) diluted in PBS-Tween-bovine serum albumin buffer was added (50 μl per well), and the mixture was incubated for 1 h at 37°C and washed as before. Finally, 50 μl of the substrate (0.4 mg/ml *O*-phenylene-diamine dihydrochloride; ICN Biomedicals Inc., Irvine, CA) in pH 5 citrate-disodium phosphate buffer containing 0.02% hydrogen peroxide was added. The reaction was stopped after 15 min with 3 N sulfuric acid, and readings were taken at 490 nm in a laboratory microplate reader (MRX; Dinex Technologies, Inc., Chantilly, VA).

To define a cutoff value for the ELISA that distinguishes negative from positive samples, the sera from 50 specific-pathogen-free (SPF) chickens (obtained from the Central Veterinary Laboratories, Ministry of Agriculture, Uruguay) plus two positive controls (see below) were evaluated 10 times by two different operators. The average of all optical density (OD) values of the SPF chicken sera plus 2 standard deviations (SD) was calculated and defined as the threshold value.

For analysis of the sera taken during the survey, each ELISA plate included

two positive-control and two negative-control sera. Positive controls were a positive-control serum (PC1) obtained from R. Davies (Central Veterinary Laboratories Weybridge, United Kingdom) and a pool of sera from chickens experimentally infected with *S. Enteritidis* (PC2). Negative controls were a pool of the sera from SPF birds (NC1) and a single SPF chicken serum (NC2). PC1/NC1 and PC2/NC2 ratios were calculated for the 10 plate determinations described above, and the average and SD values were registered. For plate validation, both ratios were calculated and the plate was validated when the ratios fell within the previously determined averages ± 2 SD.

RST. The RST was performed by standard methods previously described (48). Briefly, equal volumes of crystal violet-stained polyvalent somatic antigen and serum were mixed in a glass slide; the results were read in 2 min maximum. Known positive and negative controls were examined together with each batch of samples.

gm ELISA. Sera were processed using a commercial ELISA kit (FlockChek Se assay; IDEXX Laboratories, Inc., Westbrook, ME) specifically designed to detect antibodies to *Salmonella* Enteritidis in serum or egg yolk by following the manufacturer's instructions. The method is a gm flagellin-based assay that relies on anti-flagellar antibody in the sample to inhibit the subsequent binding of the enzyme conjugate, preventing color development in the positive sera. A flock was considered positive when it contained at least one positive serum result by this method.

Statistical analysis. The hypothesis test for difference between proportions (two-proportion z test), Fisher's exact test, and the odds ratio (OR) were used to evaluate the differences between the proportion of positive flocks or positive sera corresponding to different groups of birds (e.g., breeders versus layers, vaccinated versus not vaccinated). An alpha value of 0.05 was used.

The prevalence of *Salmonella* in eggs was estimated by using a pooled prevalence estimate for a perfect test with exact confidence limits, using EpiTools software available from AusVet Animal Health Services, Australia.

Microbiological survey. The prevalence of *Salmonella* in eggs was surveyed by evaluating a representative sample of eggs available commercially. Farms covering the whole country and different scales of production were randomly selected for evaluation, and based on data on their market share, 300 to 1,200 eggs were collected from each of them. A total of 12,400 eggs from 21 different poultry farms were evaluated; 15 of these farms had also been surveyed within the serological survey (Table 1).

The surface of the eggs was thoroughly cleaned with soap and water and disinfected twice with 70% ethanol. Egg contents were pooled in groups of 20 eggs per pool, placed in sterile plastic bags, and incubated for 24 h at 37°C. The day after, 10 ml per pool was added to 100 ml of peptone water and incubated for 18 h for pre-enrichment. One milliliter of each pre-enriched sample was added to 10 ml of tetrathionate broth and selenite-cystine broth, incubated for 24 h, and plated on both Brilliant Green agar and xylose lysine desoxycholate agar (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom). Suspect colonies were further tested by standard metabolic and biochemical tests, and those that were identified as salmonellae were serotyped using somatic and flagellum-specific sera at the National *Salmonella* Center.

Sixty hens from each of the 34 poultry flocks were sampled by cloacal swab culture, and 38 environmental samples were taken, looking for *Salmonella*. At 16 farms, feed samples were also taken (100 g from each farm). Environmental contamination was determined by dragging swabs made moist with skim milk across the floor and other surfaces in contact with birds for 10 min (5). Cloacal samples were processed in pools of 20 swabs each (three pools per flock). Environmental and feed samples were cultivated by pre-enrichment in peptone water, enrichment in tetrathionate and selenite-cystine broth, and plating in MacConkey, Brilliant Green, and XLT4 (xylose lysine Tergitol-4) agar supplemented with novobiocin (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom) (49).

Antibiotic susceptibility. All *Salmonella* isolates were tested for their antibiotic susceptibility patterns by the standard disk diffusion method in Mueller-Hinton agar, and the results were interpreted in accordance with the criteria of the Clinical and Laboratory Standards Institute (8). The strains were screened for resistance to the following antibiotics (Oxoid, Basingstoke, United Kingdom): ampicillin, nalidixic acid, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, and chloramphenicol. Strains showing ampicillin resistance were further tested against cephalothin, cefoxitin, cefuroxime, ceftriaxone, ceftazidime, ampicillin-sulbactam, and amoxicillin-clavulanic acid. The double-disk synergy test was used to screen for the production of extended-spectrum β -lactamases as described previously (27). Detection of inducible β -lactamases was performed by the disk approximation test, placing a 30- μ g cefoxitin disk near ceftriaxone, ceftazidime, and cefuroxime disks as described previously (31). Strains showing nalidixic acid resistance were tested for resistance to ciprofloxacin. In all cases, *Escherichia coli* ATCC 25922 and ATCC 35218 were used as reference strains.

For quinolone-resistant strains, the presence of the *qnr* gene was investigated by PCR under previously described conditions (26).

Random amplified polymorphic DNA (RAPD) PCR. All *Salmonella* isolates were genotyped by the RAPD PCR method using four arbitrary primers (P1254 [CCGCAGCCAA], 23L [CCGAAGCTGC], OPA-4 [AATCGGGCTG], and OPB-15 [CCAGGGTGTT]) as previously described for *S. Enteritidis* (3). The PCR products were electrophoresed in 2% agarose gels using 0.5 \times Tris-borate buffer. Only bands whose sizes fell between 200 and 2,000 bp were considered for defining amplification patterns. Patterns were considered different when they differed by more than two bands. A RAPD profile was assigned to each strain by using the combination of patterns obtained with each primer.

PCR for virulence genes. The presence of the *avrA*, *sopE*, and *spvC* genes was evaluated by a multiplex PCR assay using *invA*-specific primers (GTGAAATT ATCGCCACGTTCCGGGCAA and TCATCGCACCGTCAAAGGAACC) as an internal control (32). The respective primers for *spvC* (CCCCATAATAGG CCTAATCT and TTAATCTGTGCATCAAACGAT), *sopE* (CAGACCCGTGA AGCTATACT and AATTGCTGTGGAGTCGGCAT), and *avrA* (GTTATGG ACGGAACGACATCGG and ATTCTGCTTCCCGCGCC) were previously described (21, 36, 41). PCR was performed with 4 mM MgCl₂, 0.3 μ M *avrA* primers, 0.3 μ M *invA* primers, 0.2 μ M *sopE* primers, 0.6 μ M *spvC* primers, and 5 U of *Taq* polymerase (Invitrogen) per 100 μ l of PCR mixture. The reaction was performed using an annealing temperature of 51°C, annealing and denaturation times of 1 min each, and 35 cycles. Products were electrophoresed in 2.5% Tris-borate-EDTA agarose.

Comparative genomic hybridization (CGH) analysis. One strain each of *S. Derby* and *S. Enteritidis* isolated from eggs was analyzed by CGH using the *Salmonella* generation III microarray (1, 11) and the *S. Enteritidis* PT4 P125109 sequenced strain (45) as references. The array is nonredundant and contains coding sequences from the following eight genomes: *S. enterica* serovar Typhi (*S. Typhi*) CT18, *S. Typhi* Ty2, *S. Typhimurium* LT2 (ATCC 700220), *S. Typhimurium* DT104 (NCTC 13348), *S. Typhimurium* SL1344 (NCTC 13347), *S. Enteritidis* PT4 P125109 (NCTC 13349), *S. Gallinarum* 287/91 (NCTC 13346), and *S. bongori* 12419 (ATCC 43975).

Total DNA (including plasmid DNA) was extracted from each strain using a Genome DNA extraction kit (Promega) and quantified by agarose gel electrophoresis. Each DNA sample was diluted to 0.1 μ g/ml, sonicated for 10 s (level 2, Virsonic 300 sonicator), and then labeled with Cy5 (test) or Cy3 (control) by using the Bioprime kit (Gibco-BRL) according to the manufacturer's instructions. Labeled DNA from *S. Enteritidis* PT4 (control sample) and one of the query *Salmonella* strains (experimental sample) were mixed in equal volumes and concentrations. Dye swap labeling experiments were also performed with each test sample. Mixed labeled DNA was cleaned using an Amersham Autoseq G-50 column, denatured, and precipitated, and the resulting probes were hybridized to the microarray slide for 17 h at 49°C in a hybridization chamber (Genetix X2530). Washing procedures were stringent (two washes at 65°C in 2 \times SSC [1 \times SSC is 0.15 M NaCl plus 0.015 M sodium citrate]–0.1% sodium dodecyl sulfate for 30 min and two washes at 65°C in 0.1 \times SSC for 30 min).

Hybridization to microarray slides was detected by using a Genepix 4000B scanner (Axon Instruments, Inc.) and quantified by using Genepix Pro software (Axon Instruments, Inc.). Signal intensities were corrected by subtracting the local background values. Normalization was performed across all features on the microarray before any filtering took place. Data were median normalized, and the total list of 6,871 genes was filtered by removing those spots with a high background and genes without data in at least one of the replicates (three slides per strain, duplicate features per slide). After filtering, a list of 5,695 genes was obtained that corresponded to genes that presented a valid signal in at least one of the strains analyzed. Normalization and filtering were performed using GeneSpring microarray analysis software V7.2 (Silicon Genetics). Data analysis was performed on Excel files, following criteria previously described (4).

Calling of genes present in the PT4 genome (4,087 genes). Spots showing low signal intensity when hybridized with PT4 DNA (i.e., the median contribution of the reference signal replicates to the total signal among the lowest 5% of the PT4 genes) were designated "uncertain." For all of the other genes, the median of the ratios of the query strain to PT4 was registered and those with ratios higher than 0.67 were designated "present" in the query strain whereas those with ratios lower than 0.33 were designated "absent/divergent" in the query strain. Intermediate ratios were registered as "uncertain."

Calling of genes absent from the PT4 genome (1,608 genes). If the median contribution of all spots per gene was among the top 70% of the genes represented on the array and the query strain/PT4 signal ratio was higher than 2.5, the gene was defined as "present" in the query strain. If the median contribution was among the bottom 20% of the genes in the array, the gene was called "absent." Spots that fell outside these categories were called "uncertain."

TABLE 2. Serology results for layer hens

Farm	No. of sera tested	No. positive ^a			
		RST	LPS ELISA	Total	gm ELISA
A	189	0	11	11	0
B	183	27	57	74	0
C	949	19	61	78	0
D	189	61	13	67	27
E	186	14	3	17	0
F	0	NT	NT	NT	NT
G	339	18	41	54	3
H	181	8	81	82	0
I	0	NT	NT	NT	NT
J	0	NT	NT	NT	NT
K	183	78	59	100	28
L	189	7	9	15	0
M	0	NT	NT	NT	NT
N	191	125	49	129	129
N	198	14	4	18	0
O	0	NT	NT	NT	NT
P	0	NT	NT	NT	NT
Q	181	37	36	63	6
R	0	NT	NT	NT	NT
S	182	68	27	74	14
T	189	14	11	24	1
7	185	34	23	52	3
Total ^b	3,714	524	485	858	211

^a Values indicate positive results for each test. NT, not tested (no flocks sampled for serology). One flock was tested for each farm, except for farms G and C, where two and five flocks, respectively, were sampled.

^b Total numbers correspond to 27 sampled flocks, including the 20 flocks sampled for serology.

For validation, we applied this method to predict present/absent genes in *S. Typhi* CT18 and *S. Typhimurium* DT104 sequenced strains and found an error rate of less than 1%.

Microarray data accession number. Raw microarray data and grid files were submitted to ArrayExpress with accession number E-TABM-603 (<http://www.ebi.ac.uk/microarray-as/ae/browse.html?keywords=E-TABM-603>).

RESULTS

Serological survey. The code names assigned to the farms, the characteristics of the birds, and the number of sera sampled per farm are indicated in Table 1. Two different screening methods, LPS ELISA and an RST, were used to assess a total of 5,751 sera as described in Materials and Methods. The results of the serological survey are presented in Tables 2 and 3 for layers and breeders, respectively, and taken together, we found that 979 (485 + 494) and 751 (524 + 227) sera tested positive as evaluated by LPS ELISA and RST, respectively. Similarly, we found that the sera of 858 layers (Table 2) and of 543 breeders (Table 3) tested positive by either of the two screening methods, which corresponds to 24.4% of the birds (1,401 out of 5,751) showing evidence of infection by at least one of these two methods (Table 4). Positive sera were found in all of the flocks sampled. All positive sera were retested by an *S. Enteritidis*-specific gm ELISA. As shown, 8 out of 20 flocks of layer hens (Table 2) and 4 out of 14 flocks of breeders (Table 3) had birds than tested positive. Thus, only 12 out of the 34 flocks analyzed presented at least one positive serum sample.

Further analysis revealed that although the percentage of positive results obtained by either of the two screening meth-

TABLE 3. Serology results for breeder hens^a

Farm	No. of sera tested	No. positive			
		RST	LPS ELISA	Total	gm ELISA
Layer-breeders					
14	153	0	54	54	0
19	139	82	106	113	1
20	151	0	4	4	0
26	99	0	5	5	0
27	99	6	30	33	0
30	149	3	8	11	0
31	151	0	63	63	0
33	168	0	37	37	0
34	157	0	7	7	0
Broiler-breeders					
2	150	10	0	10	0
3	153	5	7	11	2
4	158	6	0	6	0
25	160	15	40	46	5
32	150	100	133	143	141
Total ^b	2,037	227	494	543	149

^a One flock was tested for each farm. Values indicate positive results for each test.

^b A total of 14 flocks were tested.

ods did not differ between the different groups of birds (layers, layer-breeders, and broiler-breeders), the gm ELISA results were markedly different between groups (Table 4). The differences between any two groups were significant ($P < 0.0001$ by Fisher's exact test and $P < 0.0002$ by a difference-between-proportions test). The highest percentage of birds positive for anti-gm antibodies was found among broiler-breeders (19.2%), whereas layer-breeders presented the lowest estimated frequency (less than 0.1%). Laying hens had odds of being positive in the gm-ELISA that were more than 100 times those of layer-breeder hens (OR = 106.3; 95% confidence interval [CI], 14.83 to 762.0). Broiler-breeders had odds of being positive that were six times those of laying hens (OR = 6.67; 95% CI, 4.81 to 9.25).

Since previous vaccination of the flocks with any of the available vaccines (see Materials and Methods) might result in serum antibodies that could potentially interfere with the serological survey, farm owners were asked to report whether vaccination had been used on their own farms. Of 29 farms surveyed by serology, 9 had previously vaccinated their flocks. These farms comprised 13 flocks of which 9 had been vacci-

TABLE 4. Estimated prevalence of infection based on different serological tests for different groups of birds

Type of birds	No. of sera tested	No. of positive results ^a	
		Screening	gm ELISA
Laying hens	3,714	858 (23.10)	211 (5.68)
Layer-breeders	1,266	327 (25.83)	1 (0.08)
Broiler-breeders	771	216 (28.02)	148 (19.20)
Total	5,751	1,401 (24.36)	360 (6.26)

^a Values indicate sera positive in screening tests (LPS ELISA and/or RST) or gm ELISA. Each value in parentheses is the estimated percent prevalence of positive infection.

TABLE 5. *Salmonella* isolates from eggs and correlation with gm ELISA results

Farm	Positive gm ELISA ^c	No. of egg pools analyzed ^b	No. positive for ^a :			
			<i>S.</i> Enteritidis	<i>S.</i> Derby	<i>S.</i> Gallinarum	<i>S.</i> Panama
A	No	60		3	2	
B	No	30				
C	No	40		6	1	
D	Yes	30				1
E	No	35		12		
F	NT	30	1			
G	Yes	30	1		5	
H	No	35				
I	NT	25			1	
J	NT	25				
K	Yes	25				
L	No	35		3		
M	NT	20				
N	Yes	30	2	2		
Ñ	No	20				
O	No	20				
P	NT	25		1		
Q	Yes	20				
R	NT	35		8		
S	Yes	30	4			
T	Yes	20		4		1
Total		620	8	39	9	2

^a Data indicate the number of positive pools (*Salmonella* isolation).
^b Each pool included 20 eggs.
^c No, all tested sera were negative. Yes, one or more tested sera were positive. NT, not tested (not sampled for serological studies).

nated with the *S. Gallinarum* 9R vaccine, 3 with inactivated *S. Enteritidis* SEI vaccine, and 1 with both (Table 1). All birds from the nine flocks vaccinated with 9R alone tested negative by gm ELISA. Only two flocks vaccinated with SEI vaccine and one vaccinated with both vaccines included birds that tested positive by the gm ELISA. However, *Salmonella* was also isolated from eggs or from the environment at two of these farms. Overall, these results strongly suggest that previous vaccination did not bias the prevalence results obtained. As for the 20 farms where no vaccine had been used, they comprised 21 flocks, of which 9 had birds that tested positive by the gm ELISA. Considering all of the flocks together, nonvaccinated

flocks had odds of testing positive by gm-ELISA (OR = 3.03; 95% CI, 0.6439 to 14.26) that were three times those of vaccinated flocks, although these differences lacked statistical significance. However, if the analysis was conducted considering the results of individual sera, it emerged that those animals from nonvaccinated flocks or from flocks vaccinated with SEI had odds of testing positive that were more than 30 times those of animals vaccinated with 9R vaccine (OR = 30.91; 95% CI, 12.76 to 74.87; *P* < 0.0001).

Bacterial cultures. *Salmonella* could not be recovered from environmental samples, with the exception of a single *S. Enteritidis* isolate that was recovered from a broiler-breeder flock (farm 32) (Table 3) in which most of the birds (141 out of 150) tested positive by the gm ELISA. Similarly, all cloacal swab samples were negative for *Salmonella*.

Twelve thousand four hundred eggs from 21 different farms were assessed in pools of 20 for the presence of *Salmonella* within the eggs. *Salmonella* was recovered from 58 out of 620 pools, indicating that during the period of surveillance at least 1 of every 214 eggs (58 of 12,400) in the country was contaminated with *S. enterica*. This value represents an estimated prevalence of 0.0049 (95% CI, 0.0037 to 0.0063). The isolates were recovered from within eggs from 13 different poultry farms and were serotyped as *S. Derby* (O:1,4,[5],12:fg:[1,2]; 39 isolates), *S. Gallinarum* (O:1,9,12:–:–; 9 isolates), *S. Enteritidis* (O:1,9,12:g,m:–; 8 isolates), and *S. Panama* (O:1,9,12:l,v:1,5; 2 isolates) (Table 5). At 5 of the 13 farms, we isolated more than one *Salmonella* serovar. Thus, the prevalence of *S. Enteritidis* in eggs was estimated to be 0.0006 (95% CI, 0.0003 to 0.0013). Seven *S. Enteritidis* isolates were from eggs from farms that were also sampled for serology in this study.

Subtyping of strains isolated from eggs. All *S. Enteritidis* isolates had the same RAPD amplification pattern for all of the primers tested (Fig. 1A) and were susceptible to all of the antibiotics tested. All of the isolates were also positive for three virulence genes evaluated (*sopE*, *avrA*, and *spvC*), with the exception of a single isolate (32/02) that gave a negative PCR result for *spvC* (Table 6). All of the *S. Derby* isolates had a single RAPD profile and were susceptible to all of the antibiotics tested. PCR typing with the same three virulence genes




FIG. 1. (A) *S. Enteritidis* RAPD patterns obtained using the OPA-4 primer. Lanes 1 to 8, *S. Enteritidis* egg isolates. Lane 9, 100-bp ladder. Lane 10, environmental isolate. All strains correspond to RAPD profile I. (B) *S. Gallinarum* RAPD patterns obtained using the OPA-4 primer. Lanes 1 to 5 and 8 correspond to RAPD profile VI. Lanes 6 and 7 correspond to RAPD profile IV. Lane 9 corresponds to RAPD profile V.

TABLE 6. Characterization of *Salmonella* strains isolated from eggs

Serovar (no. of strains) and farm	No. of strains	RAPD profile ^a	Virulence typing (<i>avrA sopE spvC</i>)	ATB profile ^b
Enteritidis (8)		I	+++	S
F	1	I	+++	S
G	1	I	+++	S
N	2	I	+++	S
S	3	I	+++	S
S	1	I	++-	S
Derby (39)		II	+- -	S
A	3	II	+- -	S
C	6	II	+- -	S
E	11	II	+- -	S
L	3	II	+- -	S
N	2	II	+- -	S
P	1	II	+- -	S
R	7	II	+- -	S
T	4	II	+- -	S
N	1	II	+- -	S
R	1	II	+- -	S
Panama (2)		III	+ - -	R1
T	1	III	+ - -	R1
D	1	III	+ - -	R1
Gallinarum (9)		IV	+++	S
G	2	IV	+++	S
G	1	V	+++	R3
G	2	VI	++-	S
A	2	VI	++-	R2
C	1	VI	++-	R2
I	1	VI	++-	R2

^a RAPD profiles correspond to a combination of amplification patterns obtained with four primers as described in Materials and Methods.

^b ATB profile, antibiotic resistance profile. S, susceptible to all drugs tested. R1, resistant to ampicillin, cephalothin, cefuroxime, and ceftazidime and susceptible to all other antibiotics tested. R2, resistant to nalidixic acid and susceptible to all other antibiotics tested. R3, intermediate susceptibility to ampicillin and susceptible to all other antibiotics tested.

showed that all of the *S. Derby* isolates were positive for *avrA* but negative for *sopE* and *spvC* (Table 6). Similarly, both *S. Panama* isolates had the same RAPD profile and were positive for *avrA* and negative for *sopE* and *spvC*. These two isolates were resistant to ampicillin, cephalothin, cefuroxime, and ceftazidime and susceptible to all of the other antibiotics tested.

Among the nine *S. Gallinarum* isolates, we found three antibiotic susceptibility patterns. One group (S) included four isolates that proved susceptible to all of the antibiotics tested. A second group (R2) included four isolates that were resistant to nalidixic acid and susceptible to all of the other antibiotics tested. PCR results of amplification of the *qnr* gene were negative in nalidixic acid-resistant isolates (results not shown). The third profile (R3) corresponded to a single strain that had intermediate susceptibility to ampicillin but showed susceptibility to all of the other antibiotics tested. RAPD analysis also allowed the discrimination of three different genetic profiles among these isolates (Fig. 1B). Profile IV comprised two susceptible isolates, profile V comprised a single isolate with intermediate susceptibility to ampicillin, and profile VI comprised six isolates, four of which were resistant and two susceptible to nalidixic acid. Three *S. Gallinarum* isolates were positive for *avrA*, *sopE*, and *spvC*, and the other six were negative for *spvC* (Fig. 2).

All of these results are summarized in Table 6.

CGH analysis. A particularly surprising finding was that *S. Derby* isolates markedly outnumbered the *S. Enteritidis* isolates from eggs, since during the *S. Enteritidis* epidemic there were no reported cases of human infection with *S. Derby* in Uruguay. These results could suggest that these *S. Derby* isolates have an impaired capacity to infect humans. To gain more knowledge about the differences between *S. Enteritidis* and *S. Derby* isolates and search for genetic differences that could be the basis of such marked differences in epidemiological behavior, we performed a microarray-based genomic comparison between one *S. Enteritidis* (SEN-251/01) egg isolate and one *S. Derby* (SDER-N11) egg isolate. The *S. Enteritidis* isolate selected is representative of the major genetic profile circulating in Uruguay, and it appears identical to the PT4 reference strain with regard to chromosomally located genes (4).

Of the 4,078 genes from the PT4 chromosome analyzed by CGH, 276 are absent from *S. Derby* (Table 7). Around 30% of these genes correspond to phage-encoded features, including *S. Enteritidis* phages SE10, SE12 (*S. Enteritidis sopE* phage), SE14, and SE20 (45). Another 20% of the absent genes correspond to surface structures, including the fimbrial *sef* and *lpf* operons, as well as various inner and outer membrane proteins, periplasmic and secreted proteins, and membrane transporters. Various genetic regions identified as related to virulence and pathogenicity were also predicted to be absent from *S. Derby*. These include the complete *Salmonella* pathogenicity island 13 (SPI-13) and SPI-14 regions, as well as part of SPI-6 (including various genes encoding Rhs family proteins and SafA lipoprotein) and part of SPI-10 that comprises the complete *sef* operon.

The use of the pan-*Salmonella* array also allowed us to find a number of genes predicted to be present in *S. Derby* but which are absent from the *S. Enteritidis* PT4 P125109 chromosome. These include 152 features in the array that correspond to *S. Typhi* CT18, *S. Typhimurium* LT2, *S. Typhimurium* DT104, or *S. bongori* sequenced strains (Table 8). Among these genes, we found phage-borne genes (27%) plus genes encoding surface structures (26%). An important number of features present in *S. Derby* (19%) correspond to genes of unknown function.

DISCUSSION

S. Enteritidis has been reported for the last 10 to 15 years to be widely distributed in Argentina, Chile, and Brazil (6, 16, 17).




FIG. 2. Multiplex PCR results for *S. Gallinarum* isolates. Lanes 1 to 5, isolates from farm G; lanes 6 and 7, isolates from farm A; lane 8, isolates from farm I; lane 9, isolates from farm C; lane 10, an *S. Enteritidis* isolate used as a positive control.

TABLE 7. CGH results considering genes present in the PT4 chromosome that are predicted to be absent from the *S. Derby* strain analyzed

SEN systematic	Present ^a in:	Predicted function/annotation
0030-0038 ^c	CT18, LT2, DT104	Sulfatases, secreted proteins
0110A	NO	
0139	CT18	Putative aldo/keto reductase
0141	CT18	Putative LysR family transcriptional regulator
0216	NO	Putative viral enhancing factor
0273-0274	NO	Part of SPI-6, Rsh-associated protein
0281	NO	Fimbrial subunit
0308	LT2, DT104	Pseudogene
0356	NO	Putative autotransporter/virulence factor
0392-0393	CT18, LT2, DT104	DeoR transcriptional regulator
0641	LT2, DT104, SL1344	Putative inner membrane protein
0800-0806 ^c	CT18, LT2, DT104	SPI-14
0910	NO	Putative hypothetical protein
0912	NO	Putative Gifsy2 prophage tail fiber
0916A-0921	LT2, DT104	Phage SE10
0988-0994 ^c	CT18, LT2, DT104	Secreted proteins, Na/Glu cotransporters, membrane transporters
0998	NO	Putative exported protein
1000-1009	NO	ROD-9 ^b
1013	NO	Conserved hypothetical protein
1107	CT18	Putative membrane protein
1131-1155	NO	Phage SE12 (SopE)
1157	NO	Hypothetical protein
1158	LT2, DT104	Putative integrase (pseudogene)
1172	CT18, LT2, DT104	Putative membrane protein
1176	CT18, LT2, DT104	Transposase (pseudogene)
1379-1395	NO	Phage SE14
1423A	LT2, DT104	Hypothetical protein
1432-1436	NO	Part of ROD-13
1485	LT2, DT104	FdnG
1545-1546	CT18, LT2, DT104	RspA, YnfA
1555	CT18, LT2, DT104	Conserved hypothetical protein
1558	CT18, LT2, DT104	Putative ABC transporter membrane protein
1751-1759	NO	ROD-17
1922-1966	NO	Phage SE20
1972-1987	NO	Membrane, pilin-like, exported, and hypothetical proteins
2085A-2085D	CT18	Rfb
2225-2226	CT18, LT2	Phage genes (pseudogenes)
2378	CT18	Putative LPS modification acyltransferase
2420	NO	Putative exported protein
2494	CT18, DT104	RatB, putative lipoprotein (pseudogene)
2613-2614	NO	Unknown
2719	CT18, LT2, DT104	IagB, cell invasion protein
2746A	LT2, DT104	
2781	NO	Putative transposase
2800	LT2, DT104	Hypothetical protein
2870	CT18, LT2, DT104	Hypothetical protein
2878-2879	CT18, LT2, DT104	Hipot virulence protein, endonuclease
2960-2966 ^c	LT2, DT104	SPI-13
3112-3113	LT2, DT104	Inner membrane, cytoplasmic protein
3167	CT18, LT2, DT104	Cytosine deaminase
3305	LT2, DT104	Putative surface-exposed virulence protein (BigA)
3381	LT2, DT104	Homology to death protein of phage P1
3459-3463 ^c	LT2, DT104	<i>lpf</i> operon
3474-3476 ^c	CT18, LT2, DT104	Acetyltransferases
3512	CT18, LT2, DT104	Putative lipoprotein
3572-3573	LT2, DT104	Part of SPI-3
3577	CT18, LT2, DT104	Part of SPI-3
3643-3647 ^c	LT2, DT104	Galactonate operon
3650-3651	CT18, LT2, DT104	LysR family transcriptional regulator
3820	CT18, LT2, DT104	Putative lipase
3862-3870 ^c	CT18, LT2, DT104	ABC transporters
3887	CT18, LT2, DT104	Hypothetical protein
3896-3898	CT18	ROD-34
3904-3910 ^c	LT2, DT104	PTS ^d system
3924	CT18, LT2, DT104	Vitamin B ₁₂ receptor protein
3978-3981	CT18	ROD-35
4165-4166	CT18	ROD-37
4199-4200	CT18, LT2, DT104	RelB, RelE
4246-4251	CT18	SPI-10 <i>sef</i> operon
4284-4294	NO	Type I restriction modification system

^a Indicates when the complete region or gene is present in the sequenced CT18, LT2, and/or DT104 strains.
^b ROD indicates the regions of difference between *S. Enteritidis* and *S. Typhimurium* previously described by Thomson et al. (45).
^c Indicates the genetic regions (including at least three contiguous genes) that are present in the sequenced strains of prevalent serovars Enteritidis and Typhimurium (LT2, DT104, DT2, and D23580).
^d PTS, phosphotransferase system.

Similarly, in Uruguay, *S. Enteritidis* started to be frequently isolated since 1995, and we report here the results of an epidemiological survey aimed at evaluating the extent of *S. Enteritidis* infection of poultry in the country. The survey was conducted over 2 years, and while it was taking place, an epidemic of food-borne disease was traced to poultry products containing *S. Enteritidis*. In the survey, serological analysis was emphasized because cloacal swabs were expected to yield false-

TABLE 8. CGH results considering genes absent from the PT4 chromosome that are predicted to be present in the *S. Derby* strain analyzed^a

Systematic	Present ^b in:	Predicted function/annotation
AYGAL3309	NO	Unknown
AYSL2646	NO	Unknown
SBG0036-0038	NO	Sulfatase, sulfatase regulatory, hypothetical proteins
SBG1292	NO	MalR, maltose regulatory protein
SBG3911	NO	Hypothetical protein
SDT2028-2032	DT104	Phage proteins
SDT2055	DT104	Unknown
SDT2675	DT104	Phage protein
STM0275-0278	LT2, DT104	Putative cytoplasmic, periplasmic proteins
STM0571-0577	LT2, DT104	PTS ^c system, inner membrane protein
STM1551	LT2, DT104	Putative cytoplasmic protein
STM1896	LT2, DT104	Putative cytoplasmic protein
STM2087-2089	LT2, DT104	Rfb (abequose transferase, synthetase)
STM2694	LT2	Fels-2 phage
STM2793	LT2	Fels-2 phage
STM3291	LT2, DT104	Putative cytoplasmic protein
STM4200-4208	LT2, DT104	Phage proteins
STM4210-4217	LT2, DT104	Putative cytoplasmic, inner membrane proteins
STM4417-4436	LT2, DT104	Inner membrane, DNA binding, enzymes
STM4488	LT2, DT104	Phage protein
STM4503	LT2, DT104	Putative inner membrane protein
STY0333	CT18	SPI-6, Safe
STY0290-0294	CT18, LT2, DT104	SPI-6
STY0297-0298	CT18, LT2, DT104	SPI-6
STY0302-0310	CT18, LT2, DT104	SPI-6
STY0313-0314	CT18	SPI-6
STY0756-0768	CT18, LT2, DT104	DNA recombinase, ABC transporter proteins, sugar transporter
STY0894	CT18	Ylii
STY1413	CT18	Hypothetical protein
STY1444	CT18, LT2, DT104	Putative glycolate oxidase
STY1911	CT18, LT2, DT104	Hypothetical protein
STY2043-2044	CT18	Putative bacteriophage protein, putative endolysin
STY2349-2350	CT18	Putative exported proteins
STY2361	CT18	Putative exported protein
STY2364	CT18	Putative exported protein
STY2690	CT18, LT2, DT104	Hypothetical protein
STY3092	CT18	Hypothetical protein
STY3093	CT18, LT2, DT104	Hypothetical protein
STY3277	CT18	SPI-8, unknown
STY3291-3292	CT18	SPI-8, unknown
STY3605-3606	CT18, LT2, DT104	YigG, YigF
STY3617-3619	CT18, LT2, DT104	Conserved hypothetical, membrane proteins
STY3643-3645	CT18	Membrane proteins
STY3675	CT18, LT2	Phage terminase, ATPase subunit
STY3819	CT18, LT2, DT104	Possible membrane transport protein
STY3922	CT18	Probable fimbrial protein
STY3948-3950	CT18	Hypothetical proteins
STY4075	CT18	Hypothetical protein
STY4208	CT18	Putative lipoprotein
STY4601-4602	CT18, LT2	SopE phage (putative regulator of late gene expression)
STY4605-4607	CT18, LT2	SopE phage (structural genes)
STY4613-4617	CT18, LT2	SopE phage (structural genes)
STY4620	CT18, LT2	SopE phage (NucD2 putative lysozyme)
STY4623-4626	CT18	SopE phage (structural genes)
STY4641-4643	CT18, LT2	SopE phage (phage regulatory proteins)
STY4706	CT18	Conserved hypothetical protein
STY4825	CT18	Phage polarity suppression protein
STY4880	CT18, LT2, DT104	YjiW, conserved hypothetical protein
STY4922	CT18	YafM, conserved hypothetical protein
TY2.14	NO	Hypothetical protein

^a STY, *S. Typhi* CT18; STM, *S. Typhimurium* LT2; SDT, *S. Typhimurium* DT104; SBG, the strain of *S. bongori* that has been sequenced; TY, *S. Typhi* Ty2. AYSL and AYGAL, unannotated features present in the microarray from *S. Typhimurium* SL1344 and *S. Gallinarum*, respectively.

^b Indicates when the complete region or gene is present in the sequenced CT18, LT2, and/or DT104 strains.

^c PTS, phosphotransferase system.

negative results due to intermittent bacterial excretion or antibiotic use in feed or water or as a prophylactic treatment. The results presented, showing a lack of isolation of *Salmonella* from cloacal cultures together with a high percentage of isolation from eggs, support this assumption.

We used two different serological tests (RST and LPS ELISA) for screening that showed complementarity in the field and allowed us to efficiently detect potentially positive samples. The gm ELISA was used as a specific and confirmatory method to detect *S. Enteritidis* infection, inasmuch as this method would discriminate between sera of birds effectively infected with *S. Enteritidis* and those that were positive in the screening tests due to vaccination with the 9R strain (the most frequently used vaccine in the country) or due to infection with other serovars of *Salmonella* O:9. Nevertheless, given the antigenic formula of *S. Derby* (1,4,12:f,g) and the observed prevalence of this serovar in eggs, it could be that some of the positive results of the gm ELISA were, in fact, due to *S. Derby* infection. However, our results suggest that this is very unlikely, since *S. Derby* was isolated from six different farms that were also evaluated by serology and only two of these included flocks that yielded positive gm ELISA results. Furthermore, from one of these two farms (farm N), we also isolated *S. Enteritidis*. *S. Enteritidis* infection in layer birds was evidenced by the presence of anti-gm antibodies in sera, as well as by egg culture. *S. Enteritidis* was isolated from eggs from three layer farms that had also been evaluated by serology (farms G, N, and S), and flocks from these farms also gave positive results when tested with the gm ELISA. However, sera from birds at four additional laying farms also showed positive results by the gm ELISA, but eggs from these farms did not contain *Salmonella* (farms K and Q) or contained *S. Panama* (farms D and T).

Broiler-breeders revealed the highest levels of infection, as assessed by serological analysis. Furthermore, the single positive environmental sample was isolated on a broiler farm. Conversely, layer-breeders were free from serological evidence of infection, with the exception of a single positive serum in the gm ELISA. This low incidence might suggest that this population is not the origin of the infection in layers, which probably occurred through horizontal transfer and might thus eventually be controlled through cleaning and disinfection, water and feed safety assessment, and vaccination.

Vaccination with any of the available vaccines was declared for fewer than half of the flocks studied. Our results show that birds from flocks that were nonvaccinated or that had been vaccinated with SEI vaccine were more frequently infected with *S. Enteritidis* than birds immunized with the 9R vaccine (OR = 30.91; 95% CI, 12.76 to 74.87; $P < 0.0001$). Birds vaccinated only with 9R did not show evidence of *S. Enteritidis* infection. These results may reflect cross-protection afforded by core LPS or proteins of vaccine strain 9R, as has previously been suggested (15). An unexpected and particularly surprising finding was the coexistence of four different serovars within commercially available eggs. It is usually accepted that the high prevalence of a particular serovar occurs when it occupies the niche left by another serovar that was previously dominant (i.e., substitution of *S. Enteritidis* for *S. Typhimurium* as the main serovar in poultry) (2, 42). We have found *Salmonella* of different serovars even within eggs obtained from the same farm. The *S. Gallinarum* strains recovered were different from

the 9R vaccine strain, since 9R has an electrophoretic pattern of a rough strain, whereas all of the strains recovered from eggs showed smooth electrophoretic profiles (results not shown). In addition, five out of nine *S. Gallinarum* isolates showed resistance traits which are not present in the vaccine strain.

We found a higher prevalence of *S. Derby* than *S. Enteritidis* in eggs. This finding is particularly intriguing because while the latter was identified as the etiological agent of the epidemic of food-borne disease, there were no reports of human infections with *S. Derby* in Uruguay in the same period of time. One reason for such a high prevalence could be that this serovar does not cause disease in chickens and thus it can be maintained without selection pressure in the population. On the other hand, we do not have a clear explanation for the lack of extensive human infection with *S. Derby* in Uruguay, but a reasonable hypothesis could be a low capacity of the *S. Derby* isolates to infect humans. PCR typing of virulence genes and CGH data revealed that *S. Derby* lacked an important number of genes previously related to virulence. Furthermore, CGH analysis showed that among the genes absent from *S. Derby*, there are genetic regions that are not only present in *S. Enteritidis* but also harbored by all of the *S. Typhimurium* isolates sequenced so far (strains LT2, DT104, SL1344, DT2, and DT23580). Considering that the majority of the worldwide human cases of salmonellosis are associated with either *S. Enteritidis* or *S. Typhimurium*, a detailed analysis of the genetic regions of difference between these prevalent serovars and serovar Derby might give clues about the basis of the ability of a particular serovar to cause human disease. Our analysis shows that nine of these regions of difference encompass at least three contiguous genes (Table 7). Some of those regions have a clear association with pathogenicity traits, including SPI-13, SPI-14, and the fimbrial *lpf* operon. BLAST analysis shows that these three regions are also present in serovars Newport, Dublin, Heidelberg, Paratyphi, Choleraesuis, Hadar, and Infantis. SPI-13 and SPI-14 were recently described as important in the pathogenesis of *S. Gallinarum* (44).

Other genetic regions absent from *S. Derby* but present in all of the sequenced *S. Enteritidis* and *S. Typhimurium* strains include a region associated with sulfatases (SEN0030-0038); the galactonate operon (SEN3643-3647); a region of several genes encoding ATP binding cassette (ABC) transporters, sugar kinases, and regulatory proteins (SEN3862-3870); and a region encoding various enzymes of the phosphotransferase system (SEN3904-3910). Sulfur is an essential element for bacterial growth and survival, and sulfatase genes are expressed under conditions of sulfur starvation, where the enzymes function in sulfate scavenging (28). Several authors have hypothesized that sulfatases may be involved in the host-pathogen interaction (10, 23, 30, 34). The role of sulfatases in the pathogenesis of *Salmonella* infections remains to be studied, but the presence of this genetic region may facilitate the survival of the pathogen in the human host, providing sulfur and carbon sources in tissues where free sulfur is limited.

Recently, it was reported that the monophasic serovar 4,12:d,-, which is highly adapted to poultry and is very rarely associated with human disease, lacks the galactonate and *lpf* operons (25). These genetic regions are present in *S. Typhimurium* and *S. Enteritidis*, which are serovars frequently asso-

ciated with food-borne disease. Our results show that *S. Derby* lacks these operons, suggesting that the function of these genes could be associated with the ability to cause human disease.

ABC transporters are integral membrane proteins universally distributed among living organisms with functions in many different aspects of bacterial physiology. They are especially important in the import of essential nutrients and the export of toxic molecules across cellular membranes (12). The SEN3862-3870 region has homologues in all of the *S. enterica* subsp. *enterica* strains sequenced to date but is not present in the strains of *S. bongori* and *S. enterica* subsp. *arizonae* that have been sequenced. These observations suggest that ABC transporters might be involved in the ability to infect mammalian hosts.

The lack of the region encoding phosphotransferase system enzymes in serovar Derby is consistent with the hypothesis that these strains are attenuated for virulence in humans. It has been reported previously that some of these enzymes play an important role in the virulence of *Salmonella* and other pathogens (29) and that this system participates in the regulation of the expression of different virulence factors in *Salmonella* (39).

Our results strongly suggest that the strains of *S. Derby* circulating in Uruguay are impaired in the ability to cause human infection. If these strains acquire virulence determinants by lateral gene transfer, *S. Derby* may emerge as a zoonotic problem. This serovar has recently been recognized as a cause of human food-borne infection in Brazil (19), China (50), and Taiwan (7), being associated with multidrug resistance by the acquisition of *Salmonella* genomic island 1. *S. Derby* was isolated from human cases of gastroenteritis and invasive disease in Uruguay before 1991, and during 2008, a number of isolates were obtained from human disease. Further characterization of these isolates is currently ongoing.

Overall, our results show extensive flock contamination with *S. enterica*, to a higher degree than expected, with different serovars coexisting within the poultry population. In contrast, data derived from sampling of isolates from the national epidemic of human gastroenteritis infection show that most cases of human infection were due to a single *S. Enteritidis* serovar, suggesting major differences in the capacities of different serovars to infect human populations.

ACKNOWLEDGMENTS

This work was jointly supported by INIA (National Institute for Agricultural Research) of Uruguay and by the Central Research Committee (CSIC) of the Universidad de la República Uruguay. Parts of this work were also supported by a project grant from the Wellcome Trust (078168/Z/05/Z).

Thanks to Elba Hernández and Alicia Rigoli for technical assistance and to Raquel Demarco for helpful suggestions for data analysis. Thanks to Robert Davies, Central Veterinary Laboratories, Weybridge, United Kingdom, for providing control sera.

REFERENCES

- Anjum, M. F., C. Marooney, M. Fookes, S. Baker, G. Dougan, A. Ivens, and M. J. Woodward. 2005. Identification of core and variable components of the *Salmonella enterica* subspecies I genome by microarray. *Infect. Immun.* **73**: 7894–7905.
- Bäumler, A. J., B. M. Hargis, and R. M. Tsois. 2000. Tracing the origins of *Salmonella* outbreaks. *Science* **287**:50–52.
- Betancor, L., F. Schelotto, A. Martínez, M. Pereira, G. Algorta, M. A. Rodríguez, R. Vignoli, and J. A. Chabalgoity. 2004. Random amplified polymorphic DNA and phenotyping analysis of *Salmonella enterica* serovar Enteritidis isolates collected from humans and poultry in Uruguay from 1995 to 2002. *J. Clin. Microbiol.* **42**:1155–1162.
- Betancor, L., L. Yim, M. Fookes, A. Martínez, N. R. Thomson, A. Ivens, S. Peters, C. Bryant, G. Algorta, S. Kariuki, F. Schelotto, D. Maskell, G. Dougan, and J. A. Chabalgoity. 2009. Genomic and phenotypic variation in epidemic-spanning *Salmonella enterica* serovar Enteritidis isolates. *BMC Microbiol.* **9**:237.
- Byrd, J. A., D. E. Corrier, J. R. DeLoach, and D. J. Nisbet. 1997. Comparison of drag-swab environmental protocols for the isolation of *Salmonella* in poultry houses. *Avian Dis.* **41**:709–713.
- Caffer, M. I., and T. Eguier. 1994. *Salmonella* Enteritidis in Argentina. *Int. J. Food Microbiol.* **21**:15–19.
- Chiu, C. H., H. L. Chen, L. S. Kao, C. Y. Yang, C. Chu, B. Doublet, K. Praud, and A. Cloeckaert. 2007. Variant *Salmonella* genomic island 1 antibiotic resistance gene clusters in *Salmonella enterica* serovar Derby isolates from humans in Taiwan. *J. Antimicrob. Chemother.* **59**:325–326.
- Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
- Cogan, T. A., and T. J. Humphrey. 2003. The rise and fall of *Salmonella* Enteritidis in the UK. *J. Appl. Microbiol.* **94**(Suppl.):114S–119S.
- Cohen, A. L., J. D. Oliver, A. DePaola, E. J. Feil, and E. F. Boyd. 2007. Emergence of a virulent clade of *Vibrio vulnificus* and correlation with the presence of a 33-kilobase genomic island. *Appl. Environ. Microbiol.* **73**: 5553–5565.
- Cooke, F. J., J. Wain, M. Fookes, A. Ivens, N. Thomson, D. J. Brown, E. J. Threlfall, G. Gunn, G. Foster, and G. Dougan. 2007. Prophage sequences defining hot spots of genome variation in *Salmonella enterica* serovar Typhimurium can be used to discriminate between field isolates. *J. Clin. Microbiol.* **45**:2590–2598.
- Davidson, A. L., E. Dassa, C. Orelle, and J. Chen. 2008. Structure, function, and evolution of bacterial ATP-binding cassette systems. *Microbiol. Mol. Biol. Rev.* **72**:317–364, table of contents.
- De Buck, J., F. Van Immerseel, F. Haesebrouck, and R. Ducatelle. 2004. Colonization of the chicken reproductive tract and egg contamination by *Salmonella*. *J. Appl. Microbiol.* **97**:233–245.
- de Jong, B., and K. Ekdahl. 2006. The comparative burden of salmonellosis in the European Union member states, associated and candidate countries. *BMC Public Health* **6**:4.
- Feberwee, A., T. S. de Vries, E. G. Hartman, J. J. de Wit, A. R. Elbers, and W. A. de Jong. 2001. Vaccination against *Salmonella* Enteritidis in Dutch commercial layer flocks with a vaccine based on a live *Salmonella* Gallinarum 9R strain: evaluation of efficacy, safety, and performance of serologic *Salmonella* tests. *Avian Dis.* **45**:83–91.
- Fernandes, S. A., A. C. Ghilardi, D. T. Tavechio, A. M. Machado, and A. C. Pignatari. 2003. Phenotypic and molecular characterization of *Salmonella* Enteritidis strains isolated in Sao Paulo, Brazil. *Rev. Inst. Med. Trop. Sao Paulo*. **45**:59–63.
- Fernandez, J., A. Fica, G. Ebensperger, H. Calfullán, S. Prat, A. Fernandez, M. Alexandre, and I. Heitmann. 2003. Analysis of molecular epidemiology of Chilean *Salmonella enterica* serotype Enteritidis isolates by pulsed-field gel electrophoresis and bacteriophage typing. *J. Clin. Microbiol.* **41**:1617–1622.
- Galanis, E., D. M. Lo Fo Wong, M. E. Patrick, N. Binsztin, A. Cieslik, T. Chalermchikit, A. Aidara-Kane, A. Ellis, F. J. Angulo, and H. C. Wegener. 2006. Web-based surveillance and global *Salmonella* distribution, 2000–2002. *Emerg. Infect. Dis.* **12**:381–388.
- Geimba, M. P., E. C. Tondo, F. A. de Oliveira, C. W. Canal, and A. Brandelli. 2004. Serological characterization and prevalence of *spvR* genes in *Salmonella* isolated from foods involved in outbreaks in Brazil. *J. Food Prot.* **67**:1229–1233.
- Hald, T., D. Vose, H. C. Wegener, and T. Koupeev. 2004. A Bayesian approach to quantify the contribution of animal-food sources to human salmonellosis. *Risk Anal.* **24**:255–269.
- Haneda, T., N. Okada, N. Nakazawa, T. Kawakami, and H. Danbara. 2001. Complete DNA sequence and comparative analysis of the 50-kilobase virulence plasmid of *Salmonella enterica* serovar Choleraesuis. *Infect. Immun.* **69**:2612–2620.
- Herikstad, H., Y. Motarjemi, and R. V. Tauxe. 2002. *Salmonella* surveillance: a global survey of public health serotyping. *Epidemiol. Infect.* **129**:1–8.
- Hoffman, J. A., J. L. Badger, Y. Zhang, S. H. Huang, and K. S. Kim. 2000. *Escherichia coli* K1 *asfA* contributes to invasion of brain microvascular endothelial cells in vitro and in vivo. *Infect. Immun.* **68**:5062–5067.
- Hormaeche, C., R. De Marco, F. Schelotto, C. Alia de Montero, C. Rivas, D. Mutti, and N. Bello. 1977. Frecuencia de serotipos identificados en el Centro de Salmonelas de Montevideo. *Rev. Urug. Patol. Clin. Microbiol.* **15**:43–47.
- Huehn, S., C. Bunge, E. Junker, R. Helmuth, and B. Malorny. 2009. Poultry-associated *Salmonella enterica* subsp. *enterica* serovar 4,12:d:– reveals high clonality and a distinct pathogenicity gene repertoire. *Appl. Environ. Microbiol.* **75**:1011–1020.
- Jacoby, G. A., N. Chow, and K. B. Waites. 2003. Prevalence of plasmid-mediated quinolone resistance. *Antimicrob. Agents Chemother.* **47**:559–562.
- Jarlier, V., M. H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer

- beta-lactam agents in *Enterobacteriaceae*: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.* **10**:867–878.
28. Kertesz, M. A. 2000. Riding the sulfur cycle—metabolism of sulfonates and sulfate esters in gram-negative bacteria. *FEMS Microbiol. Rev.* **24**:135–175.
 29. Kok, M., G. Bron, B. Erni, and S. Mukhija. 2003. Effect of enzyme I of the bacterial phosphoenolpyruvate: sugar phosphotransferase system (PTS) on virulence in a murine model. *Microbiology* **149**:2645–2652.
 30. Lestrade, P., R. M. Delrue, I. Danese, C. Didembourg, B. Taminiau, P. Mertens, X. De Bolle, A. Tibor, C. M. Tang, and J. J. Letesson. 2000. Identification and characterization of in vivo attenuated mutants of *Brucella melitensis*. *Mol. Microbiol.* **38**:543–551.
 31. Livermore, D. M. 1995. Beta-lactamases in laboratory and clinical resistance. *Clin. Microbiol. Rev.* **8**:557–584.
 32. Malorny, B., J. Hoorfar, C. Bunge, and R. Helmuth. 2003. Multicenter validation of the analytical accuracy of *Salmonella* PCR: towards an international standard. *Appl. Environ. Microbiol.* **69**:290–296.
 33. Mishu, B., J. Koehler, L. A. Lee, D. Rodrigue, F. H. Brenner, P. Blake, and R. V. Tauxe. 1994. Outbreaks of *Salmonella* Enteritidis infections in the United States, 1985–1991. *J. Infect. Dis.* **169**:547–552.
 34. Mougous, J. D., R. E. Green, S. J. Williams, S. E. Brenner, and C. R. Bertozzi. 2002. Sulfotransferases and sulfatases in mycobacteria. *Chem. Biol.* **9**:767–776.
 35. Nicholas, R. A., and G. A. Cullen. 1991. Development and application of an ELISA for detecting antibodies to *Salmonella* Enteritidis in chicken flocks. *Vet. Rec.* **128**:74–76.
 36. Pasmans, F., F. Van Immerseel, M. Heyndrickx, A. Martel, C. Godard, C. Wildemaue, R. Ducatelle, and F. Haesebrouck. 2003. Host adaptation of pigeon isolates of *Salmonella enterica* subsp. *enterica* serovar Typhimurium variant Copenhagen phage type 99 is associated with enhanced macrophage cytotoxicity. *Infect. Immun.* **71**:6068–6074.
 37. Peluffo, C., C. Hormaeche, R. De Marco, F. Schelotto, C. Alia de Montero, C. Rivas, D. Mutti, N. Bello, and M. Coubria. 1971. Frecuencia de tipos serológicos clasificados en el Centro Nacional de Salmonelas. *Revista Uruguaya de Patología Clínica y Microbiología*. **9**:143–150.
 38. Perales, I., and A. Audicana. 1988. *Salmonella* Enteritidis and eggs. *Lancet* **2**(8620):1133.
 39. Poncet, S., E. Milohanic, A. Maze, J. N. Abdallah, F. Ake, M. Larribe, A. E. Deghmane, M. K. Taha, M. Dozot, X. De Bolle, J. J. Letesson, and J. Deutscher. 2009. Correlations between carbon metabolism and virulence in bacteria. *Contrib. Microbiol.* **16**:88–102.
 40. Poppe, C. 1999. Epidemiology of *Salmonella enterica* serovar Enteritidis, p. 3–18. In A. M. Saed, R. K. Gast, M. E. Potter, and P. G. Wall (ed.), *Salmonella enterica* serovar Enteritidis in human and animals. Iowa State University Press, Ames.
 41. Prager, R., W. Rabsch, W. Streckel, W. Voigt, E. Tietze, and H. Tschape. 2003. Molecular properties of *Salmonella enterica* serotype Paratyphi B distinguish between its systemic and its enteric pathovars. *J. Clin. Microbiol.* **41**:4270–4278.
 42. Rabsch, W., B. M. Hargis, R. M. Tsois, R. A. Kingsley, K. H. Hinz, H. Tschape, and A. J. Bäuml. 2000. Competitive exclusion of *Salmonella* Enteritidis by *Salmonella gallinarum* in poultry. *Emerg. Infect. Dis.* **6**:443–448.
 43. Schroeder, C. M., A. L. Naugle, W. D. Schlosser, A. T. Hogue, F. J. Angulo, J. S. Rose, E. D. Ebel, W. T. Disney, K. G. Holt, and D. P. Goldman. 2005. Estimate of illnesses from *Salmonella* Enteritidis in eggs, United States, 2000. *Emerg. Infect. Dis.* **11**:113–115.
 44. Shah, D. H., M. J. Lee, J. H. Park, J. H. Lee, S. K. Eo, J. T. Kwon, and J. S. Chae. 2005. Identification of *Salmonella* Gallinarum virulence genes in a chicken infection model using PCR-based signature-tagged mutagenesis. *Microbiology* **151**:3957–3968.
 45. Thomson, N. R., D. J. Clayton, D. Windhorst, G. Vernikos, S. Davidson, C. Churcher, M. A. Quail, M. Stevens, M. A. Jones, M. Watson, A. Barron, A. Layton, D. Pickard, R. A. Kingsley, A. Bignell, L. Clark, B. Harris, D. Ormond, Z. Abdellah, K. Brooks, I. Cherevach, T. Chillingworth, J. Woodward, H. Norberczak, A. Lord, C. Arrowsmith, K. Jagels, S. Moule, K. Mungall, M. Sanders, S. Whitehead, J. A. Chabalgoity, D. Maskell, T. Humphrey, M. Roberts, P. A. Barrow, G. Dougan, and J. Parkhill. 2008. Comparative genome analysis of *Salmonella* Enteritidis PT4 and *Salmonella* Gallinarum 287/91 provides insights into evolutionary and host adaptation pathways. *Genome Res.* **18**:1624–1637.
 46. Voetsch, A. C., T. J. Van Gilder, F. J. Angulo, M. M. Farley, S. Shallow, R. Marcus, P. R. Cieslak, V. C. Deneen, and R. V. Tauxe. 2004. FoodNet estimate of the burden of illness caused by nontyphoidal *Salmonella* infections in the United States. *Clin. Infect. Dis.* **38**(Suppl. 3):S127–S134.
 47. Ward, L. R., J. Threlfall, H. R. Smith, and S. J. O'Brien. 2000. *Salmonella* Enteritidis epidemic. *Science* **287**:1753–1756.
 48. Wray, C. 1996. OIE manual of standards for diagnostic tests and vaccines, p. 642–650. Office International des Epizooties, Paris, France.
 49. Wray, C., and R. Davies. 1994. Guidelines on detection and monitoring of *Salmonella* infected poultry flocks with particular reference to *Salmonella* Enteritidis. Veterinary Public Health Unit, World Health Organization, Graz, Austria.
 50. Xia, S., R. S. Hendriksen, Z. Xie, L. Huang, J. Zhang, W. Guo, B. Xu, L. Ran, and F. M. Aarestrup. 2009. Molecular characterization and antimicrobial susceptibility of *Salmonella* isolates from infections in humans in Henan Province, China. *J. Clin. Microbiol.* **47**:401–409.
 51. Zhang-Barber, L., A. K. Turner, and P. A. Barrow. 1999. Vaccination for control of *Salmonella* in poultry. *Vaccine* **17**:2538–2545.